This inventor holds 1 USPTO granted patent. Top assignee: Betagenon Ab. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Innovations by Åsa Apelqvist in Diabetes Research
Introduction
Åsa Apelqvist, an accomplished inventor based in Stanford, California, has made significant contributions to the field of diabetes research. His innovative work focuses on advancing our understanding of type II diabetes through the development of unique laboratory models. With a robust background and expertise, Åsa has secured a patent that highlights his cutting-edge research.
Latest Patents
Åsa is credited with one notable patent titled "Animal and cell models for type II diabetes and their use." This patent reveals a transgenic model laboratory animal designed to study type II diabetes, featuring β-cells that express a dominant negative form (dnFGFR1c) of FGFR1c. The patent further discloses the use of the Ipf1/pdx1 promoter for regulating FGFR1c expression and explores various cellular conditions of β-cells. Notably, the invention also encompasses a method for preventing or treating type II diabetes, making it a critical advancement in therapeutic strategies.
Career Highlights
Åsa Apelqvist is currently affiliated with Betagenon AB, where he continues to leverage his expertise in biomedical research to drive innovation and discoveries that may impact diabetes treatment. His dedication to research and innovation underlines his status as a leading figure in his field.
Collaborations
Throughout his career, Åsa has collaborated with esteemed colleagues, including Helena Edlund and Alan Hart. These partnerships reflect a commitment to advancing scientific knowledge and developing breakthroughs in understanding and treating diabetes.
Conclusion
In summary, Åsa Apelqvist stands out as an innovative inventor whose work significantly contributes to diabetes research. His patented models offer promising avenues for both research and treatment, highlighting the importance of his contributions to the field. As research institutions and companies continue to explore solutions for type II diabetes, Åsa's innovations pave the way for future advancements and improvements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile